Small activating ribonucleic acid reverses tyrosine kinase inhibitor resistance in epidermal growth factor receptor‐mutant lung cancer by increasing the expression of phosphatase and tensin homolog

BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitors (TKI‐EGFRs) present a new prospect for the treatment of lung cancer. However, in clinical application, the majority of patients become TKI resistant within a year. More and more studies have shown that a loss of phosphatase and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meng, Peng, Zhongmin, Ren, Wangang, Wang, Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930969/
https://www.ncbi.nlm.nih.gov/pubmed/27385992
http://dx.doi.org/10.1111/1759-7714.12356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930969/
https://www.ncbi.nlm.nih.gov/pubmed/27385992
http://dx.doi.org/10.1111/1759-7714.12356

Ejemplares similares